Inventor · disambiguated record
Shifeng Liu
Also filed as: LIU SHIFENG
40 granted patents·13 pending applications·504 citations·filing 2004–2022
98Inventor score
Files withXENON PHARMACEUTICALS INC28CHAFEEV MIKHAIL7HANGZHOU INNOGATE PHARMA CO LTD7XIAMEN BIOTIME BIOTECHNOLOGY CO LTD3ABREO MELWYN2
Top patents by PatentIndex Score
53 records- 0195US8466188B2Use of spiro-oxindole compounds as therapeutic agentsCHAFEEV MIKHAIL·Filed 2007·Granted Jun 18, 2013·63 cites·1 claims
- 0295US7700641B2Spiro-oxindole compounds and their uses as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2006·Granted Apr 20, 2010·39 cites·41 claims
- 0394US8030488B2Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2008·Granted Oct 4, 2011·34 cites·28 claims
- 0493US8101647B2Spiro-oxindole compounds and their use as therapeutic agentsCHAFEEV MIKHAIL·Filed 2009·Granted Jan 24, 2012·35 cites·37 claims
- 0593US7767677B2Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitorsXENON PHARMACEUTICALS INC·Filed 2005·Granted Aug 3, 2010·34 cites·10 claims
- 0692US7935721B2Spiro-oxindole compounds and their uses as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2009·Granted May 3, 2011·18 cites·15 claims
- 0792US7799798B2Spiroheterocyclic compounds and their uses as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2006·Granted Sep 21, 2010·26 cites·9 claims
- 0892US7592343B2Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitorsXENON PHARMACEUTICALS INC·Filed 2005·Granted Sep 22, 2009·22 cites·6 claims
- 0992US7335658B2Pyridazine derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2004·Granted Feb 26, 2008·59 cites·95 claims
- 1091US8263606B2Spiro-oxindole compounds and their use as therapeutic agentsCHAFEEV MIKHAIL·Filed 2009·Granted Sep 11, 2012·16 cites·25 claims
- 1191US8106087B2Spiro-oxindole compounds and their uses as therapeutic agentsCHAFEEV MIKHAIL·Filed 2009·Granted Jan 31, 2012·19 cites·6 claims
- 1291US7547698B2Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)XENON PHARMACEUTICALS INC·Filed 2005·Granted Jun 16, 2009·18 cites·9 claims
- 1389US8415370B2Spiro-oxindole compounds and their uses as therapeutic agentsCHAFEEV MIKHAIL·Filed 2012·Granted Apr 9, 2013·10 cites·13 claims
- 1488US9481677B2Biaryl ether sulfonamides and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2012·Granted Nov 1, 2016·17 cites·17 claims
- 1588US7777036B2Heterocyclic derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2005·Granted Aug 17, 2010·13 cites·9 claims
- 1686US7514436B2Pyridazine derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2004·Granted Apr 7, 2009·22 cites·30 claims
- 1786US7456180B2Piperazine derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2004·Granted Nov 25, 2008·24 cites·25 claims
- 1885US7919484B2Combination therapyXENON PHARMACEUTICALS INC·Filed 2006·Granted Apr 5, 2011·10 cites·18 claims
- 1983US8063084B2Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levelsDALES NATALIE·Filed 2007·Granted Nov 22, 2011·6 cites·14 claims
- 2082US8916580B2Spiro-oxindole compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2013·Granted Dec 23, 2014·4 cites·8 claims
- 2178US8148378B2Pyridazine derivatives and their use as inhibitors of stearoyl-CoA desaturase-1 activity in a mammalGSCHWEND HEINZ W·Filed 2009·Granted Apr 3, 2012·5 cites·29 claims
- 2277US11352353B2Heterocyclic compound serving as FGFR4 inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2017·Granted Jun 7, 2022·2 cites·14 claims
- 2375US7754711B2Pyridazine derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2005·Granted Jul 13, 2010·2 cites·6 claims
- 2473US9458178B2Spiro-oxindole compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2016·1 cites·4 claims
- 2572US7919496B2Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymesXENON PHARMACEUTICALS INC·Filed 2005·Granted Apr 5, 2011·1 cites·10 claims
- 2670US10730887B2Compound containing tricyclic heteroaryl groupHANGZHOU INNOGATE PHARMA CO LTD·Filed 2017·Granted Aug 4, 2020·1 cites·17 claims
- 2768US11225492B2Heterocycles useful as anti-cancer agentsHANGZHOU INNOGATE PHARMA CO LTD·Filed 2016·Granted Jan 18, 2022·1 cites·14 claims
- 2867US7763618B2Pyridyl derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2004·Granted Jul 27, 2010·2 cites·43 claims
- 2961US2025381143A1A solid pharmaceutical compositionADLAI NORTYE BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 3060US2011009414A9Heterocyclic derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3157US10968234B2Compound containing tricyclic heteroaryl groupHANGZHOU INNOGATE PHARMA CO LTD·Filed 2020·Granted Apr 6, 2021·0 cites·19 claims
- 3256US2017114075A1Spiro-oxindole compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3355US8153636B2Pyridyl derivatives and their use as therapeutic agentsABREO MELWYN·Filed 2009·Granted Apr 10, 2012·0 cites·15 claims
- 3454US8293768B2Organic compoundsDALES NATALIE·Filed 2011·Granted Oct 23, 2012·0 cites·2 claims
- 3553US7605161B2Pyridyl derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2004·Granted Oct 20, 2009·0 cites·7 claims
- 3653US2012122909A9Spiro-oxindole compounds and their uses as therapeutic agentsCHAFEEV MIKHAIL·Filed 2011·Application pending·0 cites
- 3750US8383628B2Pyridyl derivatives and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2010·Granted Feb 26, 2013·0 cites·15 claims
- 3849US2008194616A1Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditionsXENON PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3949US2009069408A1Tricyclic compounds useful in treating iron disordersXENON PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4047US11142535B2Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitorHANGZHOU INNOGATE PHARMA CO LTD·Filed 2017·Granted Oct 12, 2021·0 cites·10 claims
- 4147US2013079354A1Pyridyl derivatives and their use as therapeutic agentsABREO MELWYN·Filed 2012·Application pending·0 cites
- 4247US2008234384A1Biaryl and biheteroaryl compounds useful in treating iron disordersXENON PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4346US12410188B2Adenosine receptor antagonistXIAMEN BIOTIME BIOTECHNOLOGY CO LTD·Filed 2020·Granted Sep 9, 2025·0 cites·4 claims
- 4446US2011294842A9Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as painCADIEUX JEAN-JACQUES·Filed 2007·Application pending·0 cites
- 4543US7951805B2Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturaseXENON PHARMACEUTICALS INC·Filed 2005·Granted May 31, 2011·0 cites·16 claims
- 4643US2007105820A1Oxindole compounds and their uses as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4743US2012035199A9Spiroheterocyclic compounds and their uses as therapeutic agentsCHAFEEV MIKHAIL·Filed 2010·Application pending·0 cites
- 4843US2008103151A9Heterocyclic compounds and their uses as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4943US2022339160A1Adenosine receptor antagonistXIAMEN BIOTIME BIOTECHNOLOGY CO LTD·Filed 2020·Application pending·0 cites
- 5041US11591328B2Highly active CSF1R inhibitor compoundXIAMEN BIOTIME BIOTECHNOLOGY CO LTD·Filed 2019·Granted Feb 28, 2023·0 cites·20 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Shifeng Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →